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ABSTRACT
Background: Large gaps exist in the implementation
of guideline recommendations for cardiovascular
disease (CVD) risk management. Electronic decision
support (EDS) systems are promising interventions to
close these gaps but few have undergone clinical trial
evaluation in Australia. We have developed
HealthTracker, a multifaceted EDS and quality
improvement intervention to improve the management
of CVD risk.
Methods/design: It is hypothesised that the use of
HealthTracker over a 12-month period will result in:
(1) an increased proportion of patients receiving
guideline-indicated measurements of CVD risk factors
and (2) an increased proportion of patients at high risk
will receive guideline-indicated prescriptions for
lowering their CVD risk. Sixty health services
(40 general practices and 20 Aboriginal Community
Controlled Health Services (ACCHSs) will be
randomised in a 1:1 allocation to receive either the
intervention package or continue with usual care,
stratified by service type, size and participation in
existing quality improvement initiatives. The
intervention consists of point-of-care decision
support; a risk communication interface; a clinical
audit tool to assess performance on CVD-related
indicators; a quality improvement component
comprising peer-ranked data feedback and support to
develop strategies to improve performance. The control
arm will continue with usual care without access to
these intervention components. Quantitative data will
be derived from cross-sectional samples at baseline
and end of study via automated data extraction.




▸ The development of a multifaceted decision
support tool and quality improvement (QI)
intervention.
▸ The methods to test the effectiveness of this inter-
vention in improving guideline-recommended
screening for cardiovascular risk and management
for individuals identified at high risk.
Key messages
▸ This study tests a novel intervention that incor-
porates point of care decision support, risk
communication and resources for patients,
health service audit tools and use of data for
supporting QI initiatives.
▸ In addition to assessing practitioner perform-
ance on indicators correlated with improved
health outcomes, the study also includes
detailed process and economic evaluations.
Strengths and limitations of this study
▸ The strengths of the study are that it assesses an
innovative complex intervention that is implemen-
ted in routine primary healthcare settings. It will
provide rigorous evidence on process, clinical and
economic outcomes and addresses an important
issue facing health systems worldwide—namely
scalable interventions that are able to achieve
improvements in performance.
▸ The main limitation is that it is conducted in one
country, Australia, and thus its generalisability
may be influenced by the prevailing health
system context.
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Open Access Protocol
Ethics and dissemination: The general practice component of the
study is approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component is approved by
the Aboriginal Health and Medical Research Council HREC. Formal
agreements with each of the participating sites have been signed.
In addition to the usual scientific forums, results will be
disseminated via newsletters, study websites, face-to-face feedback
forums and workshops.
Trial registration: The trial is registered with the Australian Clinical
Trials Registry ACTRN 12611000478910.
BACKGROUND
Cardiovascular disease burden in Australia
Despite recent gains, cardiovascular disease (CVD)
remains Australia’s biggest killer accounting for 18%
of the total disease burden and 11% of health system
expenditure in Australia.1 Aboriginal and Torres Strait
Islander peoples experience around five times greater
CVD burden than other Australians.2 Current estimates
project that by 2030 annual CVD expenditure will rise by
around 100% to $16 billion.3 Primary care-based strat-
egies that improve the uptake of best-practice recom-
mendations could substantially reduce both the
Indigenous and non-indigenous CVD burden and help
improve health system efficiencies.
Evidence-practice gaps in CVD prevention
In addition to lifestyle modification, a number of drug
therapies have been shown to be highly effective in pre-
venting cardiovascular events, primarily through modifi-
cation of blood pressure, lipids and platelet function.4–8
However, there is compelling evidence of the failure of
current clinical practice to adequately implement such
treatments, and to translate current knowledge into
maximally improved health outcomes. Three recently
completed cross-sectional studies of CVD risk manage-
ment in Australian general practice and Aboriginal
Community Controlled Health Service (ACCHS) set-
tings9–11 demonstrated that 50% of routinely attending
adults lacked sufficient recorded information to compre-
hensively evaluate vascular risk. For those identified at
high vascular risk, only around 40% were prescribed
guideline-indicated medicines. Similar findings have
been noted in other Australian studies.12–15 These
surveys have demonstrated failure to adequately imple-
ment the ‘absolue risk’ paradigm for CVD prevention.
Numerous tools are now available to estimate an indivi-
dual’s 5-year or 10-year absolute risk of coronary heart
disease and/or CVD.16–21 Despite their availability, only
a minority of Australian general practitioners (GPs) use
these risk assessment tools, and then primarily for
patient education, rather than to guide management
decisions.9 22 23 Australia’s first absolute risk assessment
guideline was released in 2009 by the National Vascular
Disease Prevention Alliance (NVDPA)17 and in 2012 this
was augmented by a single management guideline.24
Despite these guidelines now becoming available, there
remain substantial challenges in effectively implement-
ing their recommendations. We have found that
CVD-risk assessment and treatment work best when
negotiated as part of a shared decision-making
approach, taking an average of 15 min even where only
one guideline needs to be consulted.25
The role of electronic decision support in closing evidence
practice gaps
Electronic decision support (EDS) systems are among
the most promising interventions to improve uptake of
guideline-based recommendations in clinical practice. In
five systematic reviews on the effectiveness of EDS,
around two-thirds of studies demonstrated improvement
in practitioner performance.26–30 One systematic review
identified four decision support system features asso-
ciated with improved performance: incorporation in
routine work flow, provision at the time and location of
patient consultation, use of computer-based tools and
provision of treatment recommendations rather than
just assessments.28 Of 32 systems that incorporated all of
these elements, significant improvements in perform-
ance were noted in 30. There are relatively few con-
trolled evaluations of EDS systems that are integrated
with electronic health records (EHRs) in the area of
CVD.31–35 Effect sizes vary greatly depending on the vari-
ables studied and the type of EDS system. In one system-
atic review of on-screen point-of-care reminder systems
the absolute improvements ranged from 1% to 24% for
test ordering and from 3% to 28% for medication pre-
scribing.27 In New Zealand, an EDS system that is fully
integrated with the country’s most popular primary care
software has been successfully implemented.36 To date,
we are unaware of an EDS system aimed at assisting com-
prehensive cardiovascular risk management based on
Australian guidelines. Furthermore, we are not aware of
any randomised evaluations of such systems in Australian
primary care settings. Globally, few examples exist and
the evidence base remains poor.
INTERVENTION DEVELOPMENT
HealthTracker is a novel EDS system to facilitate
guideline-based assessment and management of CVD
risk. Outlined below are the key steps taken in the devel-
opment of the intervention.
Algorithm development and validation
A single screening and management algorithm was
developed based on a synthesis of recommendations
from several primary care screening and management
guidelines (table 1). The algorithm calculates a person’s
5-year absolute CVD risk based on the Framingham risk
equation and NVDPA recommendations 17 20 and pro-
vides management recommendations based on the
guidelines listed in table 1. In 2008–2009, a β-version of
HealthTracker was developed in a stand-alone software
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system and independently validated for accuracy and
compliance with the prevailing guidelines.22 In 2011,
the algorithm was extensively revised to incorporate
recommendations from newly published guidelines.
A similar validation process was then conducted consist-
ing of three levels:
▸ Level 1 was an iterative process where each of the cal-
culations programmed in the algorithm were tested
to ensure they were consistent with recommendations
from the guidelines. This was conducted using dei-
dentified data from 337 patients involved in the pilot.
Programming modifications were made where neces-
sary and all variables were retested to ensure they
were programmed correctly.
▸ Level 2 involved giving a plain language summary of
the algorithm to a research fellow who had not been
involved in the development of the algorithm. She
independently programmed the algorithm into a statis-
tical software package. Using data from 9077 patients
from three representative cross-sectional general prac-
tice surveys,9–11 we then assessed whether the outputs
from HealthTracker correlated with those generated
from the independently programmed version. For 60
of the 63 output variables HealthTracker achieved
perfect correlation with the independently pro-
grammed version. For the remaining three variables
minor programming errors were identified and
corrected.
▸ Level 3 involved user acceptance testing and scrutiny
of the algorithm by the study investigators, 20 health
professionals working in both General Practice
and ACCHSs and three national professional
organisations—the NVDPA, the Royal Australian
College of General Practitioners and the National
Prescribing Service. Following this feedback, a
number of minor algorithm and user interface
changes were incorporated into the final version of
the tool. The level 2 testing process was repeated
following these changes and perfect correlation
between HealthTracker and the independently pro-
grammed version was achieved for all variables.
Integration of HealthTracker with the primary care
electronic health record and quality improvement tools
HealthTracker interfaces with the two Australian clinical
practice software systems most commonly used in general
practice and ACCHS settings (Medical Director and Best
Practice). There are four components to the system:
▸ Point-of-care decision support: HealthTracker is built in
the Pen Computer Systems PrimaryCareSidebar,
third-party software that interacts with the primary
EHR system. Figure 1 shows the HealthTracker user
interface and its integration with the
PrimaryCareSidebar and the EHR. A prompt function
is used to encourage health professionals to conduct
a cardiovascular assessment if guideline recom-
mended. Where possible, the tool populates with
information from the patient’s record. If essential
information required for the calculation of absolute
risk is missing or out-of-date, a traffic light prompt
alerts the health professional and updated informa-
tion can be entered. If the patient is receiving subopti-
mal treatment then a traffic light recommendation is
made to consider initiation of treatment or additional
agents. Information about eligibility for the Australian
Government Pharmaceutical Benefits Scheme subsidy
is provided if lipid lowering medicines are recom-
mended. All outputs are qualified by statements
emphasising that the final decision to commence or
change therapy should be made by the health profes-
sional based on all available information.
Table 1 Guidelines used in the HealthTracker algorithm
Professional organisation Guideline
National Vascular Disease Prevention Alliance Guidelines for the Assessment of Absolute Cardiovascular Disease Risk
2009
National Heart Foundation Reducing Risk in Heart Disease 2008
Guide to Management of Hypertension 2008- Updated Aug 2009
Aspirin for cardiovascular disease prevention 2003
National Heart Foundation/ Cardiac Society of
Australia and New Zealand
The Lipid Position Statement 2005
National Stroke Foundation Clinical Guidelines for Stroke Management 2010
Royal Australian College of General
Practitioners
Guidelines for preventive activities in general practice 2009
Diabetes Australia Diabetes Management in General Practice 2010/2011
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Case
Detection and Diagnosis
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Diagnosis,
Prevention and Management of Chronic Kidney Disease
Kidney Health Australia Chronic Kidney Disease Management (CKD) in General Practice 2007
Department of Health and Aging Schedule of Pharmaceutical Benefits Scheme 2011 General Statement for
Lipid Lowering Drugs
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▸ A patient-oriented risk communication interface: A key
finding from the pilot evaluation was the role of the
output in risk communication. GPs wanted to inter-
actively alter current risk factors and perform ‘what
if’ scenarios to demonstrate to patients the effects of
current and altered risk over time. This functionality
has been built into HealthTracker and uses the
concept of ‘Heart Age’ to demonstrate to patients the
discrepancy between current risk and an ideal risk
based on well-controlled risk factor levels. Figure 2
shows an example of how a patient’s heart age
changes with the effect of smoking cessation.
▸ A data extraction tool: This provides health professionals
with immediate feedback on their performance on
screening and management of CVD risk for their
entire patient population. Figure 3 shows an example
of screening performance for a range of CVD risk
factors. Practitioners can use this tool to identify
specific patients in whom there may be a particular
risk factor measurement missing or a potential pre-
scribing gap. Customised point-of-care prompts can
then be created. When a patient record is opened an
alert is provided to notify the practitioner of the par-
ticular management issue and this can then be
actioned.
▸ A quality improvement (QI) component: This is aligned
with the methods of the Improvement Foundation of
Australia (IFA) Australian Primary Care
Collaboratives (APCC) programme. Deidentified data
extracts of clinical performance are securely exported
to a web-based central repository managed by the
IFA. This repository provides access to site-specific
feedback reports on performance compared with
other anonymised sites. Figure 4 shows an example of
how this information is presented.
STUDY OBJECTIVES
The TORPEDO study will test HealthTracker’s perform-
ance in assisting health professionals and patients in
making evidence-based management decisions to help
prevent heart attack, stroke and related conditions.
Hypotheses
Using a cluster randomised, controlled trial design, two
specific hypotheses will be tested. Compared with
control practices, those practices randomised to receive
HealthTracker will have:
1. An increased proportion of patients receiving appro-
priate (guideline-indicated) measurements of their
CVD risk factors.
2. An increased proportion of patients at high risk
receiving appropriate (guideline-indicated) prescrip-
tions for the management of their CVD risk.
These aims will be augmented by formal economic
and process evaluations to provide crucial information
on large-scale implementation and sustainability.
Figure 1 HealthTracker_user interface.
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STUDY DESIGN
HealthTracker will be evaluated using a cluster
randomised, controlled trial design. At end of study,
HealthTracker will be made available to both the inter-
vention and control arms for a further 12 months free of
any licence fees. The study schema including site and
patient eligibility criteria are highlighted in figure 5.
Eligibility criteria
Health service
1. Use of Medical Director or Best Practice for EHR
management.
2. Exclusive use of these systems to record risk factor
information, pathology test results and prescribe
medications.
3. Agreement by all GPs and other designated staff to
use HealthTracker.
Services that do not have a compliant software system
will be excluded from participation. Services using
‘hybrid’ paper and electronic systems for recording risk
factor information, pathology results and medication
prescription will also not be eligible to participate.
Patients
1. Aboriginal and Torres Strait Islander people 35+
years and all others 45+ years (age criteria are based
on NVDPA guideline screening recommendations37).
2. Attendance at the general practice or ACCHS at least
three times in the previous 24-month period AND at
least once in the previous 6-month period.
Site recruitment
Participating general practices have been recruited
from the Sydney region in collaboration with primary
healthcare organisations known in Australia as Medicare
Locals. Participating ACCHSs have been recruited in
partnership with two state representative bodies for
ACCHSs, the Aboriginal Health & Medical Research
Council (AH&MRC) of NSW and the Queensland and
Aboriginal Islander Health Council (QAIHC).
A $500AUD reimbursement to participating sites will be
made to partially compensate for health service staff
time commitment to study-related activities. Sites rando-
mised to the intervention will receive training support in
use of the system predominantly via face-to-face visits
and webinars. All licence costs and technical support
associated with the intervention will be provided free to
the intervention sites in the first 12 months and to all
sites for the following 12 months after completion of
the trial. A newsletter and networking web site will be
provided to participating sites. Royal Australian College
of General Practitioners Quality Assurance and
Continuing Professional Development points will be
offered to participating GPs in both arms of the trial.
Figure 2 HealthTracker—cardiovascular disease-risk communication interface.
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Randomisation
Sixty services (40 general practices and 20 ACCHSs) will
be randomised in a 1:1 allocation to use HealthTracker
or ‘usual care’ for 12 months. Clusters will be stratified
at three levels:
1. ACCHS versus general practices.
2. Service size (<500 patients meeting eligibility criteria
vs >=500).
3. Participation in existing QI programmes (current
involvement in one of five national and state pro-
grammes involving regular audit and feedback versus
past or never involved in these programmes).
A site assessment survey will be administered to all
sites to assess for service eligibility and these stratifying
variables. Permuted block randomisation will be cen-
trally performed using a web-based form. As this is a
pragmatic trial, allocation will be single blinded with
outcome analyses conducted blinded to treatment
allocation.
Intervention group
The intervention arm will receive the four components
of the system described above (point-of-care decision
support software, risk communication tools, data extrac-
tion tools and access to the QI portal). Clinical staff will
be given training in use of the tools and a support
service will be available for any technical queries. One
initial face-to-face training visit and subsequent site visits
and webinars targeting strategies to improve quality of
care will be provided. Unless requested by health ser-
vices the intervention will not be modified or
discontinued. Reasons for discontinuation will be out-
lined and all analyses will be conducted on an
intention-to-treat basis (see below).
Control group
Sites allocated to this arm will continue usual practice
with their current systems without the implementation
of HealthTracker. As the George Institute holds exclusive
rights to the distribution of the system, there is no possi-
bility of control sites having access to HealthTracker. If
these sites already routinely use data extraction tools for
assessing their quality of care then this will continue as
normal. As with the intervention arm, services participat-
ing in any QI initiatives will continue participation as
usual. For those sites not routinely using data extraction
tools, the automated data extraction tool will be tempor-
arily installed for data collection purposes only and then
uninstalled that same day. A feedback report on per-
formance will be provided at study completion only.
Quantitative data collection
Cross-sectional data will be collected in an automated
manner for all patients who satisfy the eligibility criteria
at each service (figure 5). These data will then be sent
securely to the George Institute via an export function
for the analysis of primary and secondary outcomes.
Prerandomisation: 1 month prior to randomisation, dei-
dentified data will be collected from all sites. These data
will be fed back to all sites as a formal report highlight-
ing areas where data quality issues may occur.
Figure 3 Sample output of performance in cardiovascular disease-risk factor screening.
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Randomisation: Baseline data will be collected and sites
will be randomised to intervention or control.
End of intervention period: At the end of 12 months,
data will be collected in both study arms.
Primary outcomes
▸ Change in the proportion of eligible patients receiv-
ing appropriate measurements of their CVD risk in
the previous 12 months (measured at randomisation
and at 12 months).
▸ Change in the proportion of eligible patients assessed
at high CVD risk receiving appropriate prescriptions
for their CVD risk factors in the previous 12 months
(measured at randomisation and 12 months).
Appropriate measurement of CVD risk factors is
defined as having recorded or updated all the essential
risk factors for the measurement of CVD risk (smoking
status, blood pressure (BP) in the previous 12 months,
total cholesterol and high-density lipoprotein (HDL)
cholesterol in the previous 24 months) among those in
whom risk assessment is guideline indicated. Unless
explicitly recorded, diagnoses of diabetes or left ven-
tricular hypertrophy will be assumed to be absent.
High CVD risk is defined as a calculated 5-year CVD
risk of >15%, a history of CVD or the presence of any
clinically high-risk conditions (as per NVDPA recom-
mendations). Based on audit data, this is expected to
comprise ∼30% of the patient population.10 11
Appropriate prescriptions is defined as a prescription
for one or more BP lowering drugs and a statin for
people at high risk without CVD; or a prescription for
one or more BP lowering drugs and a statin and an anti-
platelet agent (unless contraindicated by oral anticoagu-
lant use) for people with established CVD.
Secondary outcomes
▸ Change in the measurement of individual risk factors
separately (smoking status, BP, cholesterol, other
non-Framingham risk factors—BMI, chronic kidney
disease (CKD) screening with urinary Albumin
to Creatinine ratio, estimated Glomerular Filtration
Rate);
Figure 4 Sample display from the quality improvement portal.
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▸ Intensification of existing medication regimes among
patients at high CVD risk (additional BP and
lipid-lowering agents);
▸ Changes in mean systolic BP, total cholesterol, LDL
cholesterol and HDL cholesterol;
▸ New CVD and CKD diagnoses.
Statistical considerations
Randomisation of 60 services (30 per arm) will provide
90% power to detect a ≥10% absolute higher occur-
rence in each primary study outcome among practices
receiving HealthTracker. The following assumptions are
based on our three audits in ACCHSs and mainstream
general practices9–11 and include an assumed improve-
ment of 10% in the two primary outcomes in control
practices as a result of study participation.
1. Cluster size of eligible population will range from 200
in a small service through to 2000 in a large service.
An average cluster size of 750 is assumed.
2. Recording rates of essential risk factors needed for
risk assessment in the target group (first primary
outcome) average 50%.10 11
3. Thirty per cent of the cluster will be either be at high
CVD risk or have established CVD (n=250) and
prescription of appropriate medicines to high-risk
patients (second primary outcome) is 50%. This is
based on our published data on drug prescriptions
for individuals with and without established CVD.9–11
4. An intraclass correlation coefficient of 0.05 for both
primary outcomes based on our audit data.9–11
5. Two-sided α=0.05
Data analysis will be performed on an intention-to-
treat basis using generalised estimating equations.38
Subgroup analyses will be carried out using the three
prespecified strata: (1) ACCHS versus general practices,
(2) service size (small vs large) and (3) current partici-
pation in QI programmes vs past or no involvement in
these programmes.
Economic evaluation
The economic evaluation will have a trial-based compo-
nent and a modelled evaluation of long-term costs and
outcomes. The incremental cost will be based on soft-
ware, training and other costs incurred with transition-
ing practices to using HealthTracker. This will help
determine the cost barriers experienced by different
practices in adopting the system. Data on medications,
laboratory tests, consultations and newly recorded diag-
noses of CVD events incurred by eligible patients during
the trial will be obtained from the data extraction tools.
Costs will be calculated from prevailing Medicare rates
and standard Australian National Diagnosis Related
Groups cost weights for CVD hospitalisations. The incre-
mental cost consequences of the HealthTracker system
in achieving each of the primary outcomes will then be
estimated, for example, cost per eligible patients
assessed at high CVD risk receiving appropriate prescrip-
tions. Trial-based data, however, cannot capture costs
and outcomes beyond the trial. To address this, a mod-
elled economic evaluation will enable quality of life and
survival to be examined and allow incremental cost-
effectiveness ratios to be calculated in terms of cost per
Quality Adjusted Life Years gained. Using a Markov
model, the eligible patient population in both study
arms will be hypothetically tracked over an extended
period. Transition between various defined health states,
costs and quality of life attached to various health states
and the projected long-term intervention effects from
that observed in the trial will be based on published evi-
dence. With appropriate discounting, estimates of long-
term costs and outcomes will fold out of the model.
Sensitivity analyses will be conducted on discount rate,
uncertainty in outcome estimates and assumptions made
in costing (eg, varying efficiencies with different patient
practice ratios to those of the trial setting). This will
better inform policy makers as to the resource conse-
quences of rolling out this programme to scale.
Process evaluation
The qualitative evaluation of the β-version of
HealthTracker suggested that a critical factor affecting
the uptake of EDS interventions is whether and how
Figure 5 TORPEDO study schema.
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they become embedded in routine healthcare.22 In the
TORPEDO trial we will build on this observation
through a detailed process evaluation to better appreci-
ate the factors that might influence sustainability beyond
the trial setting. Two qualitative methods will be used to
explore these factors.
Semistructured interviews with health professionals and staff
A maximum variation sample will be taken to ensure
diverse opinions are gained from patients, clinical and
managerial health staff and sites with low and high
uptake of the intervention.39 Key issues to be explored
will include (1) how practitioners use HealthTracker;
(2) what effects it has on organisational practices and
personnel and (3) what are patients’ experiences of
being presented with HealthTracker outputs and what
impact does this have on the healthcare encounter.
Individual informed consent will be sought and data will
be collected towards the end of the intervention period
so as not to unduly influence trial outcomes.
Audio/video ethnography
A key component of understanding barriers/enablers to
use of HealthTracker is a better appreciation of how
practitioners and patients use it at the point of care.
Data collection using audio/video recording will capture
how technological innovations are actually used in prac-
tice.40 Ethnographic analysis will greatly augment the
interview accounts and will particularly shed important
light on (1) how the intervention impacts on the flow of
the clinical encounter; (2) how risk information is com-
municated between health professional and patient and
(3) how the patient receives and interprets the informa-
tion and the role it may play in shared decision-making
processes. Although audio/video recorded clinical
encounters are commonly used for primary care teach-
ing purposes, such a technique can be potentially sensi-
tive and therefore will be restricted to a small number of
sites. Recordings will be conducted toward the end of
the intervention period when both health staff and
patients are thoroughly familiar with the system. This
will occur over a 1-week period at each site. Participants
who are approached for an interview will be invited to
participate in this component. They will be given the
option of having their healthcare encounter audio or
video recorded. A follow-up interview will be arranged
with these participants (both staff and patients) where
the recording is played back for participant interpret-
ation of the data.
These data will be supplemented by project officer
field notes to identify any key processes, events, staffing
and other resource issues occurring during the
intervention period that may be relevant in gaining a
better understanding of barriers and facilitators to
implementation.
A multidisciplinary research team will guide the ana-
lysis process. As is common with qualitative inquiry, data
analysis will commence early and be conducted
contemporaneously with data collection. This method
allows for interview content to be refined for subsequent
data collection and to actively pursue emergent themes
of interest. Although interviewing will continue until
thematic saturation is achieved and therefore the exact
number of interviews is unknown, we anticipate from
prior experience that around 80 interviews (40 patients
and 40 staff) will provide sufficiently rich data to meet
our objectives.
Interview data will be digitally recorded, and profes-
sionally transcribed. NVivo 9 (QSR International
Melbourne, Victoria, Australia) will be used to assist with
data organisation and coding for key themes. Video data
will be directly analysed and coded for key themes
within NVivo. Feedback of findings to participants will
be provided by a variety of methods, including work-
shops, summary reports, newsletters and via the study
website.
ETHICAL CONSIDERATIONS
The general practice component of the study is
approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component
is approved by the Aboriginal Health and Medical
Research Council HREC. Formal agreements with each
of the participating sites have also been signed.
Quantitative data will be obtained from deidentified clin-
ical audits. Ethical approval to grant waiver of the usual
requirement to obtain individual patient consent has
been obtained. In participating ACCHS sites, eligible
patients can request to ‘opt out’ from having data in the
clinical audit data extracts exported. Data exports will be
compliant with privacy legislation, centrally managed by
the George Institute and held in strict confidence. Some
individual health professionals (GPs, practice nurses,
etc) and patient participants will have their informed
consent taken at the site to allow data collection
through semistructured in-depth interviews and/or
the use of audio/videotaped healthcare encounters.
Participation in this component will be optional. Patient
information statements and consent forms have been
approved by each ethics committee and formatted in
accordance with their own guidelines and requirements.
The study will be conducted in accordance with the
principles set out in the National Health and Medical
Research Council and the NSW Aboriginal Health and
Medical Research Council guidelines. Specific effort will
be taken to respect the autonomy and governance of
participating ACCHSs. The intellectual property rights
of ACCHSs will be recognised and preserved. It is also
recognised that ACCHSs have rights and responsibilities
regarding the use of health-related information for their
attending clients. Collaborators on the TORPEDO study
will be encouraged to disseminate information from the
project in a manner that supports health improvement
for Aboriginal and Torres Strait Islander peoples and
local benefit to participating ACCHSs.
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DISCUSSION
The TORPEDO study will seek to provide reliable evi-
dence about the effectiveness of QI interventions
incorporating EDS in Australian primary care settings.
The implications of use of such systems for CVD risk
management extend well beyond being a point-of-care
clinical resource. Improving health system performance
is central to the aims of this initiative and this is espe-
cially pertinent to addressing Aboriginal health inequi-
ties where the CVD burden is five-fold greater. There is
potential for substantially better health outcomes
from CVD in Australia with improved implementation of
existing evidence in primary healthcare, where most of
the opportunity to manage cardiovascular risk occurs.
The strategy proposed is the first of its kind in Australia
and is strongly aligned with national strategy recom-
mendations for health system reform. If effective,
HealthTracker could have widespread applicability
for the prevention and management of other chronic
diseases.
Strengths and limitations of this study
The strengths of the study are that it assesses an in-
novative complex intervention that is implemented in
routine primary healthcare settings. It will provide rigor-
ous evidence on process, clinical and economic out-
comes and addresses an important issue facing health
systems worldwide—namely scalable interventions that
are able to achieve improvements in performance.
The main limitation is that it is conducted in one
country, Australia, and thus its generalisability may be
influenced by the prevailing health system context.
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